Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
Candidate Gene Association Studies of Anthracycline-induced Cardiotoxicity: A Systematic Review and Meta-analysis.
复制标题
DOI：
10.1038/s41598-017-00075-1
复制
发表时间：
2017-02-27
影响因子：
4.6
通讯作者：
Lee SW
中科院分区：
文献类型：
--
作者：
Leong SL;Chaiyakunapruk N;Lee SW
蒽环类药物在癌症患者的治疗中发挥着重要作用，但蒽环类药物诱导的心脏毒性（ACT）的发展仍然是大多数临床医生的重要关注点。最近，遗传学方法已被用于识别ACT风险增加的患者。本系统评价评估了基因组标记物与ACT之间的关联。在Medline、PubMed、科克伦对照研究中心、CINAHL Plus、AMED、EMBASE和HuGE Navigator中进行了从开始到2016年5月的系统性文献检索。确定了28项检查遗传变异与ACT相关性的研究。这些研究检测了84个不同的基因和147个单核苷酸多态性。荟萃分析显示，3种风险变异显著增加ACT风险;即ABCC 2 rs 8187710（合并比值比：2.20; 95% CI：1.36-3.54）、CYBA rs 4673（1.55; 1.05-2.30）和RAC 2 rs 13058338（1.79; 1.27-2.52）。目前的证据仍不清楚蒽环类药物治疗前药物基因组学筛查的潜在作用。需要进一步的研究来提高ACT的诊断和预后作用。
Anthracyclines play an important role in the management of patients with cancer but the development of anthracycline-induced cardiotoxicity (ACT) remains a significant concern for most clinicians. Recently, genetic approach has been used to identify patients at increased risk of ACT. This systematic review assessed the association between genomic markers and ACT. A systematic literature search was performed in Medline, PubMed, Cochrane Central Register of Controlled Studies, CINAHL Plus, AMED, EMBASE and HuGE Navigator from inception until May 2016. Twenty-eight studies examining the association of genetic variants and ACT were identified. These studies examined 84 different genes and 147 single nucleotide polymorphisms. Meta-analyses showed 3 risk variants significantly increased the risk for ACT; namely ABCC2 rs8187710 (pooled odds ratio: 2.20; 95% CI: 1.36–3.54), CYBA rs4673 (1.55; 1.05–2.30) and RAC2 rs13058338 (1.79; 1.27–2.52). The current evidence remains unclear on the potential role of pharmacogenomic screening prior to anthracycline therapy. Further research is needed to improve the diagnostic and prognostic role in predicting ACT.